- Market Capitalization, $K 123,245
- Shares Outstanding, K 22,781
- Annual Sales, $ 0 K
- Annual Income, $ -129,070 K
- 60-Month Beta 1.24
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 4.97
|Period||Period Low||Period High||Performance|
| || |
-0.49 (-8.57%)since 10/11/19
| || |
-1.34 (-20.40%)since 08/12/19
| || |
-10.37 (-66.47%)since 11/12/18
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.
Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.
Axovant (AXGT) closed at $7.69 in the latest trading session, marking a +0.92% move from the prior day.
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.
Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
The market is approaching oversold territory. Be watchful of a trend reversal.